• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

    12/18/23 8:10:35 AM ET
    $AIMD
    $ARQT
    $BYTS
    $CCG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older.

    Arcutis Biotherapeutics shares gained 25.3% to $3.06 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Banzai International, Inc. (NASDAQ:BNZI) shares gained 120.8% to $13.60 in pre-market trading. The company completed business combination with 7GC & Co on Friday.
    • Royalty Management Holding Corporation (NASDAQ:RMCO) gained 39.8% to $3.51 in pre-market trading after falling around 20% on Friday.
    • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) shares gained 45.8% to $0.3282 in pre-market trading after dipping around 24% on Friday.
    • iCoreConnect Inc. (NASDAQ:ICCT) shares climbed 32.4% to $2.25 in pre-market trading after surging over 73% on Friday.
    • Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares rose 24.6% to $0.0567 in pre-market trading after declining 11% on Friday.
    • Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares surged 20.8% to $0.1751 in pre-market trading after falling over 6% on Friday.
    • Ontrak, Inc. (NASDAQ:OTRK) rose 19.2% to $0.4894 in pre-market trading after falling over 8% on Friday.
    • Shineco, Inc. (NASDAQ:SISI) shares gained 18.1% to $0.1127 in pre-market trading.
    • Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) gained 16.8% to $0.27 in pre-market trading after falling over 7% on Friday.

    Losers

    • Minerva Surgical, Inc. (NASDAQ:UTRS) shares fell 53.3% to $1.31 in pre-market trading. On Dec. 15, 2023, Minerva Surgical notified the Nasdaq of its intent to file a Form 25 with the SEC on or about Dec. 26, 2023 to effect the voluntary delisting of the company's common stock from Nasdaq.
    • Ebix, Inc. (NASDAQ:EBIX) shares fell 49.1% to $2.51 in pre-market trading after declining 7% on Friday.
    • Maison Solutions Inc. (NASDAQ:MSS) shares fell 24% to $1.90 in pre-market trading after dipping 83% on Friday.
    • Gaotu Techedu Inc (NYSE:GOTU) fell 21.4% to $3.64 in pre-market trading.
    • Near Intelligence, Inc. (NASDAQ:NIR) shares fell 18.7% to $0.0479 in pre-market trading after dipping 20% on Friday.
    • BYTE Acquisition Corp. (NASDAQ:BYTS) fell 18.5% to $6.53 in pre-market after tumbling 20% on Friday.
    • Ainos, Inc. (NASDAQ:AIMD) fell 18.1% to $2.72 in pre-market trading after jumping 31% on Friday.
    • Cheche Group Inc. (NASDAQ:CCG) fell 12.2% to $5.60 in pre-market trading.
    • Chavant Capital Acquisition Corp. (NASDAQ:CLAY) shares fell 11.1% to $9.33 in pre-market trading after gaining 5% on Friday.
    • Northann Corp. (NYSE:NCL) shares fell 10.1% to $14.32 in pre-market trading after surging 42% on Friday.

    Now Read This: HEICO, EMCOR Group And 3 Stocks To Watch Heading Into Monday

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $ARQT
    $BYTS
    $CCG

    CompanyDatePrice TargetRatingAnalyst
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    Arcutis Biotherapeutics Inc.
    $ARQT
    12/30/2024$19.00Buy
    H.C. Wainwright
    Arcutis Biotherapeutics Inc.
    $ARQT
    8/28/2024$15.00Buy
    Jefferies
    Gaotu Techedu Inc.
    $GOTU
    8/27/2024Buy → Sell
    Citigroup
    Gaotu Techedu Inc.
    $GOTU
    2/28/2024Underperform → Outperform
    CLSA
    Gaotu Techedu Inc.
    $GOTU
    1/3/2024$4.50Sell → Buy
    Citigroup
    Arcutis Biotherapeutics Inc.
    $ARQT
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    Ontrak Inc.
    $OTRK
    12/5/2023$4.00Buy
    ROTH MKM
    More analyst ratings

    $AIMD
    $ARQT
    $BYTS
    $CCG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

    Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeksCaregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infantsResults from additional studies across the ZORYVE portfolio being presented in three poster presentations WESTLAKE VILLAGE, Calif. and DENVER, March 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaning

    3/28/26 11:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cheche Group Schedules Second Half and FY 2025 Earnings Release and Conference Call Date

    BEIJING, March 25, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced it will host a conference call to discuss results for the Second Half and Full Year 2025 on Thursday, April 2, 2026, at 8:00 a.m. ET. The earnings release and related investor deck will be available prior to the event in the "Quarterly Results" section under "Financials", while the live webcast will be available here or in the "Events" section under the "News & Events" header on the investor relations website ir.chechegroup.com.The dial-in numbers for the conference call will be as follows:Participant (toll-free): 1-888-346-89

    3/25/26 8:00:00 AM ET
    $CCG
    Specialty Insurers
    Finance

    Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

    WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, the Company will share new efficacy, safety, and tolerability results from its INTEGUMENT-INFANT Phase 2 trial evaluating investigational once-daily ZORYVE cream 0.05% in infants aged 3

    3/18/26 8:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BYTS
    $CCG
    SEC Filings

    View All

    Maison Solutions Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Maison Solutions Inc. (0001892292) (Filer)

    3/27/26 4:07:33 PM ET
    $MSS
    Food Chains
    Consumer Staples

    SEC Form 424B3 filed by Wheeler Real Estate Investment Trust Inc.

    424B3 - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Filer)

    3/26/26 4:12:43 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    SEC Form 424B3 filed by Wheeler Real Estate Investment Trust Inc.

    424B3 - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Filer)

    3/26/26 4:10:23 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Magnetar Financial Llc

    4 - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Issuer)

    3/26/26 6:48:23 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by Stilwell Joseph

    4 - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Issuer)

    3/20/26 4:29:20 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    SEC Form 3 filed by Cheche Group Inc.

    3 - Cheche Group Inc. (0001965473) (Issuer)

    3/18/26 7:22:42 AM ET
    $CCG
    Specialty Insurers
    Finance

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ase Test, Inc. bought 29,476 shares (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    6/25/25 6:03:05 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/6/25 8:44:37 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

    Goldman initiated coverage of Arcutis Biotherapeutics with a rating of Neutral and set a new price target of $18.00

    7/25/25 9:06:04 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

    12/30/24 7:23:09 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

    Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

    8/28/24 7:20:44 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

    WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company. "As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board," said Frank Watanabe, president and chi

    12/8/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

    BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. The Division is expected to use blockchain technol

    8/13/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iCoreConnect Inc.

    SC 13G/A - iCoreConnect Inc. (0001906133) (Subject)

    12/12/24 9:44:00 PM ET
    $ICCT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/9/24 5:54:19 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13G/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/5/24 5:28:41 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    $AIMD
    $ARQT
    $BYTS
    $CCG
    Financials

    Live finance-specific insights

    View All

    Cheche Group Schedules Second Half and FY 2025 Earnings Release and Conference Call Date

    BEIJING, March 25, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ:CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced it will host a conference call to discuss results for the Second Half and Full Year 2025 on Thursday, April 2, 2026, at 8:00 a.m. ET. The earnings release and related investor deck will be available prior to the event in the "Quarterly Results" section under "Financials", while the live webcast will be available here or in the "Events" section under the "News & Events" header on the investor relations website ir.chechegroup.com.The dial-in numbers for the conference call will be as follows:Participant (toll-free): 1-888-346-89

    3/25/26 8:00:00 AM ET
    $CCG
    Specialty Insurers
    Finance

    Gaotu Techedu Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 5, 2026 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE:GOTU) ("Gaotu" or the "Company"), a leading technology-driven education company in China focused on enabling lifelong learning through AI-powered solutions, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights[1]Net revenues were RMB1,685.3 million, increased by 21.4% from RMB1,388.6 million in the same period of 2024.Gross billings[2] were RMB2,573.7 million, increased by 19.1% from RMB2,160.2 million in the same period of 2024.Loss from operations was RMB118.0 million, compared with loss from operations of RMB149.3 million in the same per

    3/5/26 1:13:00 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care